This site is intended for healthcare professionals

Kiniksa announces results from phase III trial of mavrilimumab in COVID-19-related ARDS.

Read time: 1 mins
Published:3rd Jan 2022
Kiniksa Pharmaceuticals, Ltd. announced that the Phase III portion of the Phase II/III trial of mavrilimumab in COVID-19-related acute respiratory syndrome (ARDS) did not meet the primary efficacy endpoint.

Mavrilimumab is an investigational fully human monoclonal antibody that targets granulocyte macrophage colony stimulating factor receptor alpha (GM-CSFRalfa). The Phase II/III trial is a global, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of mavrilimumab for the treatment of hospitalized, non-mechanically-ventilated adult patients with hypoxia and severe COVID-19 pneumonia/hyperinflammation.

A total of 582 patients in the Phase III portion of the trial were randomized in a 1:1:1 ratio to receive a single intravenous dose of mavrilimumab 10 mg/kg, 6 mg/kg, or placebo. The Phase III portion of the trial did not meet its primary efficacy endpoint of proportion of patients alive and free of mechanical ventilation at Day 29.

Condition: Coronavirus/ARDS
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights